In subjects with severe T2 eosinophilic phenotype asthma, the presence of comorbidities affecting the upper airways increases as peripheral eosinophilia increases and, therefore, patients with these characteristics may benefit more from treatment with IL-5/Rα, even if the anti-IL-4/13 and anti-IgE treatment are recommended as first-line treatments in these patients. Here, IL5 is linked to Increased total eosinophil count.